14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $1.58 $2.30 Thursday, 25th Apr 2024 CTMX stock ended at $1.60. This is 1.84% less than the trading day before Wednesday, 24th Apr 2024. During the day the stock fluctuated 3.54% from a day low at $1.58 to a day high of $1.64.
90 days $1.38 $2.86
52 weeks $1.04 $2.86

Historical CytomX Therapeutics prices

Date Open High Low Close Volume
Apr 25, 2024 $1.61 $1.64 $1.58 $1.60 286 285
Apr 24, 2024 $1.68 $1.70 $1.62 $1.63 279 085
Apr 23, 2024 $1.67 $1.73 $1.64 $1.68 289 726
Apr 22, 2024 $1.76 $1.76 $1.67 $1.67 257 689
Apr 19, 2024 $1.72 $1.75 $1.64 $1.67 493 890
Apr 18, 2024 $1.77 $1.79 $1.72 $1.73 198 735
Apr 17, 2024 $1.84 $1.86 $1.76 $1.76 585 190
Apr 16, 2024 $1.99 $1.99 $1.86 $1.86 316 413
Apr 15, 2024 $2.14 $2.14 $1.94 $1.97 272 148
Apr 12, 2024 $2.14 $2.25 $2.07 $2.15 923 168
Apr 11, 2024 $2.10 $2.16 $2.06 $2.15 1 011 675
Apr 10, 2024 $2.02 $2.11 $1.80 $2.10 2 455 536
Apr 09, 2024 $2.06 $2.08 $2.00 $2.03 175 110
Apr 08, 2024 $2.09 $2.10 $2.05 $2.06 175 652
Apr 05, 2024 $2.07 $2.14 $2.05 $2.06 267 857
Apr 04, 2024 $2.18 $2.18 $2.06 $2.06 267 253
Apr 03, 2024 $2.13 $2.18 $2.08 $2.15 516 249
Apr 02, 2024 $2.15 $2.15 $2.07 $2.14 325 963
Apr 01, 2024 $2.19 $2.20 $2.09 $2.15 319 497
Mar 28, 2024 $2.20 $2.30 $2.17 $2.18 2 853 490
Mar 27, 2024 $2.12 $2.20 $2.08 $2.19 589 998
Mar 26, 2024 $2.16 $2.16 $1.99 $2.11 645 908
Mar 25, 2024 $2.13 $2.15 $2.09 $2.14 357 741
Mar 22, 2024 $2.21 $2.21 $2.10 $2.11 287 756
Mar 21, 2024 $2.23 $2.31 $2.21 $2.24 449 875
Click to get the best stock tips daily for free!

About CytomX Therapeutics

CytomX Therapeutics CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme... CTMX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT